Form 4: Kymera COO Jeremy Chadwick Executes Stock Option Plan

Kymera Therapeutics COO Jeremy G. Chadwick exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, exercised options to acquire 300 shares of common stock.
• The acquisitions consisted of 100 shares at $30.17 and 200 shares at $43.50.
• Following the acquisition, 300 shares were sold at a price of $90.00 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-arranged plan and represents a negligible portion of the executive's total equity stake.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The executive maintains a significant beneficial ownership of 61,202 shares following the transaction.

Negatives

• The executive reduced their total beneficial ownership by 300 shares through the exercise and immediate sale process.

Risks

• Future share price volatility may impact the value of remaining unvested stock options held by the executive.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of individual insider transaction activity.

Industry Context

StockSavvy.ai notes that routine 10b5-1 trading plan activity by C-suite executives in the biotechnology sector is standard practice for liquidity management and does not typically signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while avoiding potential insider trading concerns.
• The volume of shares traded (300) is immaterial relative to the executive's total holdings of 61,202 shares.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and small in scale.

Next Steps

• Continued vesting of remaining stock options in accordance with the established 36-month schedules.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Biotech, Rule 10b5-1